Alzheimer's Treatment Window

Therapeutic window simulator — early-stage Alzheimer's diagnosis and treatment timing.

Current Stage

—

—

Eligibility status

—

Benefit potential

—

Window status

—

Diagnostic urgency

—

Disease stageMCI

Years since symptom onset0.0 yr

Healthy neuron

Impaired neuron

Amyloid plaque

Treatment window marker

Scroll for details

Placeholder title: the MCI-to-dementia continuum

Placeholder lead sentence on the Alzheimer's disease stage spectrum.

~15%: MCI prevalence (Placeholder cohort note)
~10-15%/yr: Conversion rate (Placeholder progression note)
Placeholder: Mild dementia onset (Placeholder marker)
Placeholder: Moderate dementia (Placeholder marker)

Placeholder section heading: defining the spectrum

Placeholder paragraph describing the disease stage spectrum.

Placeholder key insight about the disease spectrum.

Placeholder title: treatment efficacy declines with stage

Placeholder lead sentence on efficacy differences across stages.

Placeholder: MCI response (Placeholder note)
Placeholder: Mild dementia response (Placeholder note)
Placeholder: Moderate dementia response (Placeholder note)
Placeholder: Trial endpoint (Placeholder note)

Placeholder section heading: efficacy by stage

Placeholder paragraph describing efficacy differences by stage.

Placeholder key insight about efficacy decline.

Placeholder title: the therapeutic window narrows

Placeholder lead sentence on the narrowing treatment window.

Placeholder: Window open (Placeholder note)
Placeholder: Window narrowing (Placeholder note)
Placeholder: Window closed (Placeholder note)
Placeholder: Key driver (Placeholder note)

Placeholder section heading: why the window narrows

Placeholder paragraph describing why the window narrows with progression.

Placeholder key insight about window narrowing.

Placeholder title: early diagnosis enables early treatment

Placeholder lead sentence on early diagnosis pathways.

Placeholder: Biomarker lead time (Placeholder note)
Placeholder: Diagnostic delay today (Placeholder note)
Placeholder: PET/CSF biomarkers (Placeholder note)
Placeholder: Blood biomarkers (Placeholder note)

Placeholder section heading: diagnostic pathways

Placeholder paragraph describing early diagnosis pathways.

Placeholder key insight about early diagnosis benefit.

Placeholder title: stage-based eligibility criteria

Placeholder lead sentence on eligibility criteria for treatment.

Placeholder: Label restriction (Placeholder note)
Placeholder: Amyloid PET required (Placeholder note)
Placeholder: ARIA monitoring (Placeholder note)
Placeholder: APOE4 consideration (Placeholder note)

Placeholder section heading: eligibility criteria

Placeholder paragraph describing stage-based eligibility criteria.

Placeholder key insight about eligibility limits.